表紙:TROP2抗体の世界市場 - 臨床試験の考察:2026年
市場調査レポート
商品コード
1035802

TROP2抗体の世界市場 - 臨床試験の考察:2026年

Global TROP2 Antibody Market & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 90 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

TROP2抗体の世界市場 - 臨床試験の考察:2026年
出版日: 2021年11月10日
発行: KuicK Research
ページ情報: 英文 90 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

TROP2 (Trophoblast surface antigen 2) は、上皮細胞の膜表面に存在する細胞表面タンパク質で、細胞の自己再生、増殖、形質転換に関与しています。TROP2は、正常な生理条件下では、胚の発生、胎盤組織の形成、胚の着床、幹細胞の増殖、臓器の発生などに関与していることが明らかになっています。さらに、TROP2はいくつかのがん細胞に高度に発現しており、一般的にがん細胞の攻撃性と関連していることも明らかになっています。また、TROP2は、がん細胞の成長や増殖につながるいくつかのシグナル伝達経路にも関与しています。したがって、TROP2を標的とすることは、がんを標的とするための代替手段になる可能性があります。

当レポートでは、世界のTROP2抗体市場について調査分析し、市場分析、市場機会評価、販売考察、臨床試験の考察、主な市場力学、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 TROP2標的療法市場のイントロダクション

  • 概要
  • TROP2標的療法の歴史

第2章 TROP2はがんの理想的な臨床バイオマーカー

第3章 TROP2標的療法の機序

第4章 世界のTROP2標的療法市場分析

  • 現在の市場シナリオ
  • 将来の市場機会

第5章 世界のTROP2標的療法市場機会:地域別

  • 米国
  • 欧州
  • 日本
  • その他の地域

第6章 世界のTROP2標的療法市場:がん別

  • 乳がん
  • 尿路上皮がん
  • 肺がん
  • 膵臓がん
  • 前立腺がん

第7章 最初に承認されたTRO2標的抗体 - Trodelvy (Sacituzumab Govitecan)

  • 概要
  • 承認、特許・独占権

第8章 Trodelvy - 商業情報

  • 用量・価格分析
  • 販売分析

第9章 Trodelvyの販売予測

第10章 TROP2標的療法の臨床試験の考察

  • フェーズ別
  • 開発状況別
  • 地域別

第11章 世界のTROP2標的療法市場 - 進行中の研究開発

  • Datopotamab Deruxtecan (DS-1062)
  • SKB264
  • JS108
  • BAT 8003
  • Trodelvy (Sacituzumab Govitecan)

第12章 世界のTROP2標的療法の市場力学

  • 市場促進要因
  • 市場課題

第13章 世界のTROP2標的療法市場の将来の見通し

第14章 競合情勢

  • Amunix
  • ARIUS Research
  • AstraZeneca
  • Biothera
  • Daiichi Sankyo Company
  • Gilead
  • Immunomedics
  • Janux Therapy
  • Klus Pharma
  • Myeloid therapeutics
  • Pfizer Inc
  • Shanghai Junshi Bioscience
図表

LIST OF FIGURES

  • Figure 1-1: Evolution of TROP2 Targeting Therapeutics
  • Figure 2-1: Frequency of TROP2 Expression by Cancer Type (%)
  • Figure 2-2: Role of TROP2 in Cancer
  • Figure 3-1: TROP2 Stimulated Effectors, Biomarker & Pathways
  • Figure 3-2: TROP2 Regulated Oncogenic Cell Signaling Pathways
  • Figure 3-3: General Mechanism of TROP2 Targeting Therapy
  • Figure 3-4: Trodelvy - Mechanism of Action
  • Figure 4-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 4-2: Global - Number of Cancer Deaths (Million), 2020, 2025 & 2030
  • Figure 4-3: Global - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 4-4: Global - Cancer Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-5: Global - TROP2 Targeting Therapy Market by Product (%) 2026
  • Figure 5-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-2: US - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 5-3: US - TROP2 Targeting Therapy Market by Product (%), 2026
  • Figure 5-4: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-5: Europe - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022-2026
  • Figure 5-6: Europe - TROP2 Targeting Therapy Market by Product (%), 2026
  • Figure 5-7: UK - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022 - 2026
  • Figure 5-8: Switzerland - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022 - 2026
  • Figure 5-9: Japan - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-10: Japan - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022-2026
  • Figure 5-11: Japan - TROP2 Targeting Therapy Market by Product (%), 2026
  • Figure 5-12: ROW - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022-2026
  • Figure 5-13: ROW - TROP2 Targeting Therapy Market by Product (%), 2026
  • Figure 5-14: Canada - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022 - 2026
  • Figure 5-15: Australia - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022 - 2026
  • Figure 6-1: Global - Number of Newly Diagnosed Breast Cancer Cases (Million), 2021-2026
  • Figure 6-2: Global - Number of Newly Diagnosed Triple Negative Breast Cancer Cases, 2021-2026
  • Figure 6-3: Global - Breast Cancer TROP2 Targeting Therapy Market Opportunity (US$ Million), 2021 - 2026
  • Figure 6-4: Global - Number of Urotheluial Cancer Cases, 2021-2026
  • Figure 6-5: Global - Urothelial Cancer TROP2 Targeting Therapy Market Opportunity (US$ Million), 2021-2026
  • Figure 6-6: Global - Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026
  • Figure 6-7: Global -TROP2 Targeting Therapy Market Opportunity in Lung Cancer (US$ Million), 2023 - 2026
  • Figure 6-8: Global - Number of Newly Diagnosed Pancreatic Cancer Cases, 2020-2026
  • Figure 6-9: Global - Number of Newly Diagnosed Prostate Cancer Cases (Million), 2020-2026
  • Figure 6-10: Global - Number of Newly Diagnosed Castration Positive Prostate Cancer Cases, 2020-2026
  • Figure 6-11: Global - Estimated Adoption Rates for TROP2 Targeting Therapy for Castration Positive Prostate Cancer, 2021-2026
  • Figure 7-1: Trodelvy - Response Rate in Clinical Study (%)
  • Figure 7-2: Trodelvy - FDA Approval Year Indication
  • Figure 7-3: Trodelvy - Patent Expiration Year by Region
  • Figure 7-4: Trodelvy - FDA Orphan Designation Year by Indication
  • Figure 8-1: Trodelvy - Average Cost of Single Dose Cycle & Single Treatment Cycle (US$), September'2021
  • Figure 8-2: Global - Trodelvy Quarterly Sales Value (US$ Million), Q2 - Q4' 2020
  • Figure 8-3: Global - Trodelvy Quarterly Sales Value (US$ Million), Q1 - Q3' 2021
  • Figure 8-4: Trodelvy - US & Europe Sales Value (US$ Million), Q3'2021
  • Figure 9-1: Global - Trodelvy Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-2: US - Trodelvy Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-3: Europe - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-4: Japan - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-5: ROW - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-6: UK - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-7: Switzerland - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-8: Canada - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-9: Australia - Trodelvy Sales Forecast (US$ Million), 2022 - 2026
  • Figure 10-1: Global - Number of TROP2 Related Clinical Trials by Phase, September'2021
  • Figure 10-2: Global - TROP2 Related Clinical Trials by Phase (%), November'2021
  • Figure 10-3: Global - Number of TROP2 Related Clinical Trials by Development Status, November'2021
  • Figure 10-4: Global - Number of TROP2 Related Clinical Trials by Development Status (%), November'2021
  • Figure 10-5: Global - Number of TROP2 Related Clinical Trials by Region, November'2021
  • Figure 11-1: Investigational TROP2 Targeting Therapeutics
  • Figure 11-2: DS1062a Phase II Trial - NSCLC Study Initiation & Completion Year
  • Figure 11-3: DS1062a Phase II Trial - Metastatic NSCLC Study Initiation & Completion Year
  • Figure 11-4: DS1062a Phase III Trial - Comparitive Study Initiation & Completion Year
  • Figure 11-5: DS1062a Phase I Trial - Study Initiation & Completion Year
  • Figure 11-6: DS1062a Phase I Combinational Trial - Metastatic NSCLC Study Initiation & Completion Year
  • Figure 11-7: SKB264 Phase I-II Trial - Study Initiation & Completion Year
  • Figure 11-8: JS108 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-9: BAT8003 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-10: IMMU132 Phase II Trial - Prostate Cancer Study Initiation & Completion Year
  • Figure 11-11: IMMU132 Phase II Trial - Endometrial Carcinoma Study Initiation & Completion Year
  • Figure 11-12: IMMU132 Phase II Trial - Metastatic Solid Tumors Study Initiation & Completion Year
  • Figure 11-13: IMMU132 Phase I-II Trial - Epithelial Cancer Study Initiation & Completion Year
  • Figure 11-14: IMMU132 Phase II Trial - Glioblastoma Study Initiation & Completion Year
  • Figure 12-1: Global TROP2 Targeting Therapy Market Drivers
  • Figure 12-2: Challenges for Global TROP2 Targeting Therapy Market
  • Figure 12-3: US - Annual Cost Comparison of TROP2 Targeting Therapy with other Treatments (US$), November '2021
目次

“Global TROP2 Antibody Market & Clinical Trials Insight 2026” Report Analysis and Data Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion
  • Market and Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 1 Drugs
  • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026
  • Future Market Assessment By Indication Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

Trophoblast surface antigen 2 (Trop2) is a cell surface protein which spans the epithelial membrane surface and plays role in cell self-renewal, proliferation, and transformation. Under normal physiological conditions, Trop2 has demonstrated its role in embryonic development, placental tissue formation, embryo implantation, stem cell proliferation, and organ development. Further, studies have also demonstrated that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to cancer cell growth and proliferation. Therefore, targeting Trop2 can be an alternative to target cancer.

Recently, scientists developed novel antibody drug conjugate in which the therapeutic antibody is targeted towards Trop2, thereby delivering the cytotoxin to the surface of tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody drug conjugate which has been approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The introduction of Trodelvy in 2020 is expected to witness high growth rates in market due to lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and will significantly improve the survival outcomes.

Beyond the approval of Trodelvy in US, it has also gained approval in Australia, Canada, UK, and Switzerland for adults with metastatic TNBC. Apart from this, the drug is present in regulatory view in other regions including Europe, China and Singapore. Recently, European Medicines Agency has recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months. The rapid approval of drug in different regions will fuel the growth of market in coming years.

The quick approval of Trodelvy has further empowered innovation and development in this sector. To date, a cocktail of Trop2 targeted drugs including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development. These drugs have been designed to target a wide range of cancer including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others. Apart from this, several investigational studies are also ongoing to evaluate the efficacy of Trodelvy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. The forthcoming years will see rapid influx of Trop-2 targeted therapies in wide range of cancers.

The key players in the TROP2 Antibody market include Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution, and others. The major players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market. For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.

The global Trop2 targeting drug market is expected to surpass US$ 4 Billion by 2026. Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers, and rise in awareness of Trop-2 targeting drug owing o high efficiency will propel the growth of market. In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.

Table of Contents

1. Introduction to TROP2 Targeting Therapy Market

  • 1.1 Overview
  • 1.2 History of TROP2 Targeting Therapeutics

2. TROP2 Ideal Clinical Biomarker for Cancer

3. TROP2 Targeting Therapeutics Mechanism

4. Global TROP2 Targeting Therapy Market Analysis

  • 4.1 Current Market Scenario
  • 4.2 Future Market Opportunity

5. Global TROP2 Targeting Therapy Market Opportunity by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 Rest of World

6. Global TROP2 Targeting Therapy Market by Cancer

  • 6.1 Breast Cancer
  • 6.2 Urothelial Carcinoma
  • 6.3 Lung Cancer
  • 6.4 Pancreatic Cancer
  • 6.5 Prostate Cancer

7. First Approved TRO2 Targeting Antibody - Trodelvy (Sacituzumab Govitecan)

  • 7.1 Overview
  • 7.2 Approval, Patent & Exclusivity

8. Trodelvy - Commercial Information

  • 8.1 Dosage & Price Analysis
  • 8.2 Sales Analysis

9. Trodelvy Sales Forecast 2026

10. TROP2 Targeted Therapy Clinical Trials Insight

  • 10.1 By Phase
  • 10.2 By Development Status
  • 10.3 By Region

11. Global TROP2 Targeting Therapy Market - Ongoing Research & Development

  • 11.1 Datopotamab Deruxtecan (DS-1062)
  • 11.2 SKB264
  • 11.3 JS108
  • 11.4 BAT 8003
  • 11.5 Trodelvy (Sacituzumab Govitecan)

12. Global TROP2 Targeted Therapy Market Dynamics

  • 12.1 Market Drivers
  • 12.2 Market Challenges

13. Global TROP2 Targeting Therapy Market Future Outlook

14. Competitive Landscape

  • 14.1 Amunix
  • 14.2 ARIUS Research
  • 14.3 AstraZeneca
  • 14.4 Biothera
  • 14.5 Daiichi Sankyo Company
  • 14.6 Gilead
  • 14.7 Immunomedics
  • 14.8 Janux Therapy
  • 14.9 Klus Pharma
  • 14.10 Myeloid therapeutics
  • 14.11 Pfizer Inc
  • 14.12 Shanghai Junshi Bioscience